Valenstein, Max L. http://orcid.org/0000-0001-7616-0148
Rogala, Kacper B. http://orcid.org/0000-0001-5997-7770
Lalgudi, Pranav V.
Brignole, Edward J. http://orcid.org/0000-0002-4285-6128
Gu, Xin http://orcid.org/0000-0002-3393-6927
Saxton, Robert A.
Chantranupong, Lynne
Kolibius, Jonas
Quast, Jan-Philipp http://orcid.org/0000-0003-2713-778X
Sabatini, David M.
Article History
Received: 29 August 2021
Accepted: 7 June 2022
First Online: 13 July 2022
Competing interests
: D.M.S. is a shareholder of Navitor Pharmaceuticals, which is targeting the amino-acid-sensing pathway upstream of mTORC1 for therapeutic benefit.